Immediate Post-Treatment Response
Placeholder: rapid symptom drop is often seen within days of dosing.
- 24–72h: Response window (Placeholder timeframe)
- ~60%: Responders (Placeholder rate)
- Variable: Score drop (Placeholder magnitude)
- Low: Adverse events (Placeholder note)
Acute effects
Placeholder: session followed by short integration support period.
Baseline comparison
Placeholder: scores compared against pre-treatment severity baseline.
1-Month Follow-Up Assessment
Placeholder: first formal check to confirm gains are holding steady.
- High: Retention of gains (Placeholder estimate)
- ~90%: Follow-up rate (Placeholder completion)
- Minimal: Symptom rebound (Placeholder observation)
- 1–2: Support contacts (Placeholder count)
Integration check-in
Placeholder: brief interview assesses mood and functioning shifts.
Early warning signs
Placeholder: clinicians watch for early symptom creep here.
3–6 Month Durability Check
Placeholder: mid-range window tests whether the plateau is stable.
- ~3–4mo: Plateau length (Placeholder duration)
- ~45%: Stable responders (Placeholder share)
- ~30%: Partial relapse (Placeholder share)
- ~25%: Full relapse (Placeholder share)
Plateau dynamics
Placeholder: symptom curve typically flattens before any decline.
Risk stratification
Placeholder: lower initial response linked to earlier decline onset.
12-Month Long-Term Outcome
Placeholder: year-long view shows gradual decline in many cases.
- ~35%: Durable response (Placeholder rate)
- Variable: Score at 12mo (Placeholder trend)
- ~20%: Return to baseline (Placeholder share)
- Common: Repeat treatment (Placeholder note)
Long-term trajectory
Placeholder: single course rarely guarantees permanent remission.
Comparative context
Placeholder: outcomes vary versus standard maintenance pharmacotherapy.
Booster Session Consideration
Placeholder: decision point on scheduling a reinforcing booster dose.
- ~40%: Booster uptake (Placeholder estimate)
- High: Re-response rate (Placeholder after booster)
- 6–12mo: Typical timing (Placeholder window)
- 50%+: Risk threshold (Placeholder trigger)
Decision criteria
Placeholder: relapse risk score guides the booster recommendation.
Booster protocol
Placeholder: repeat session mirrors the original dosing structure.